EGFR Inhibitor as Second-Line Therapy in a Patient With Mutant RAS Metastatic Colorectal Cancer: Circulating Tumor DNA to Personalize Treatment

JCO Precis Oncol. 2018 Nov:2:1-6. doi: 10.1200/PO.17.00277.

Authors

Paola Gazzaniga¹, Cristina Raimondi¹, Federica Urbano¹, Enrico Cortesi¹

Affiliation

¹ All authors: Sapienza University of Rome, Rome, Italy.

PMID: 35135115
DOI: 10.1200/PO.17.00277

No abstract available